Targeting the CD47-SIRPα signaling axis: current studies on B-cell lymphoma immunotherapy

被引：15

作者：

Zhang, Jin ^{[1
]}

Jin, Shenhe ^{[1
]}

Guo, Xiaojun ^{[2
]}

Qian, Wenbin ^{[3
,4
]}

机构：

[1] Zhejiang Univ, Sir Run Run Shaw Hosp, Coll Med, Dept Hematol, Hangzhou, Zhejiang, Peoples R China

[2] Jiaxing Univ, Affiliated Hosp 1, Dept Hematol, Jiaxing, Peoples R China

[3] Zhejiang Univ, Affiliated Hosp 1, Coll Med, Inst Hematol, Hangzhou, Zhejiang, Peoples R China

[4] Zhejiang Univ, Affiliated Hosp 1, Coll Med, Malignant Lymphoma Diag & Therapy Ctr, Hangzhou, Zhejiang, Peoples R China

来源：

JOURNAL OF INTERNATIONAL MEDICAL RESEARCH | 2018年 / 46卷 / 11期

关键词：

ANTIBODY-MEDIATED PHAGOCYTOSIS; INTEGRIN-ASSOCIATED PROTEIN; CD47 INDUCES APOPTOSIS; PROMOTE PHAGOCYTOSIS; MONOCLONAL-ANTIBODY; THERAPEUTIC TARGET; CANCER; EXPRESSION; LEUKEMIA; BLOCKADE;

D O I：

10.1177/0300060518799612

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

The function of the immune system in cancer initiation and progression has been widely examined. Notably, immunotherapy has become a promising approach for cancer treatment. CD47, a member of the immunoglobulin superfamily, plays an important role in the immune regulation of cancer by binding to SIRP alpha. Multiple studies have detected high CD47 expression on the surface of tumor cells, which indicates poor prognosis. Treatments that block the interaction of CD47 and SIRP alpha significantly suppress tumor growth and metastasis through diverse mechanisms, such as phagocytosis, antibody-dependent cellular cytotoxicity, and apoptosis. Recently, several studies have reported increased CD47 expression on different types of lymphoma cells, indicating that the CD47-SIRP alpha pathway can be used as a therapeutic target in lymphoma. This review focuses on the role of CD47-SIRP alpha in B-cell lymphoma and discusses promising therapeutic strategies targeting the CD47-SIRP alpha axis, which yield insights into the immunotherapy of B-cell lymphoma.

引用

页码：4418 / 4426

页数：9

共 52 条

[1] Co-expression of MET and CD47 is a novel prognosticator for survival of luminal-type breast cancer patients [J].

Baccelli, Irene ;

Stenzinger, Albrecht ;

Vogel, Vanessa ;

Pfitzner, Berit Maria ;

Klein, Corinna ;

Wallwiener, Markus ;

Scharpff, Martina ;

Saini, Massimo ;

Holland-Letz, Tim ;

Sinn, Hans-Peter ;

Schneeweiss, Andreas ;

Denkert, Carsten ;

Weichert, Wilko ;

Trumpp, Andreas .

ONCOTARGET, 2014, 5 (18) :8147-8160

[2] Caspase-independent type III programmed cell death in chronic lymphocytic leukemia: the key role of the F-actin cytoskeleton [J].

Barbier, Sandrine ;

Chatre, Laurent ;

Bras, Marlene ;

Sancho, Patricia ;

Roue, Gael ;

Virely, Clemence ;

Yuste, Victor J. ;

Baudet, Sylvie ;

Rubio, Manuel ;

Esquerda, Josep E. ;

Sarfati, Marika ;

Merle-Beral, Helene ;

Susin, Santos A. .

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 (04) :507-517

[3] INTEGRIN-ASSOCIATED PROTEIN - A 50-KD PLASMA-MEMBRANE ANTIGEN PHYSICALLY AND FUNCTIONALLY ASSOCIATED WITH INTEGRINS [J].

BROWN, E ;

HOOPER, L ;

HO, T ;

GRESHAM, H .

JOURNAL OF CELL BIOLOGY, 1990, 111 (06) :2785-2794

[4] Chimeric antigen receptor T-cell therapies for lymphoma [J].

Brudno, Jennifer N. ;

Kochenderfer, James N. .

NATURE REVIEWS CLINICAL ONCOLOGY, 2018, 15 (01) :31-46

[5] The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications [J].

Chao, Mark P. ;

Weissman, Irving L. ;

Majeti, Ravindra .

CURRENT OPINION IN IMMUNOLOGY, 2012, 24 (02) :225-232

[6] Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy [J].

Chao, Mark P. ;

Tang, Chad ;

Pachynski, Russell K. ;

Chin, Robert ;

Majeti, Ravindra ;

Weissman, Irving L. .

BLOOD, 2011, 118 (18) :4890-4901

[7] Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma [J].

Chao, Mark P. ;

Alizadeh, Ash A. ;

Tang, Chad ;

Myklebust, June H. ;

Varghese, Bindu ;

Gill, Saar ;

Jan, Max ;

Cha, Adriel C. ;

Chan, Charles K. ;

Tan, Brent T. ;

Park, Christopher Y. ;

Zhao, Feifei ;

Kohrt, Holbrook E. ;

Malumbres, Raquel ;

Briones, Javier ;

Gascoyne, Randy D. ;

Lossos, Izidore S. ;

Levy, Ronald ;

Weissman, Irving L. ;

Majeti, Ravindra .

CELL, 2010, 142 (05) :699-713

[8] Drug therapy: Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma [J].

Cheson, Bruce D. ;

Leonard, John P. .

NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (06) :613-626

[9] Selective Blockade of the Ubiquitous Checkpoint Receptor CD47 Is Enabled by Dual-Targeting Bispecific Antibodies [J].

Dheilly, Elie ;

Moine, Valery ;

Broyer, Lucile ;

Salgado-Pires, Susana ;

Johnson, Zoe ;

Papaioannou, Anne ;

Cons, Laura ;

Calloud, Sebastien ;

Majocchi, Stefano ;

Nelson, Robert ;

Rousseau, Francois ;

Ferlin, Walter ;

Kosco-Vilbois, Marie ;

Fischer, Nicolas ;

Masternak, Krzysztof .

MOLECULAR THERAPY, 2017, 25 (02) :523-533

[10] Suppressed Expression of Homotypic Multinucleation, Extracellular Domains of CD172 (SIRP-) and CD47 (IAP) Receptors in TAMs UpRegulated by Hsp70-Peptide Complex in Dalton's Lymphoma [J].

Gautam, P. K. ;

Acharya, A. .

SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2014, 80 (01) :22-35

← 1 2 3 4 5 6 →